Navigation Links
Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07,Teleconference to Answer Questions About TA-65, Their Telomerase,Activator With Proven Age Management Benefits

NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase Activation Sciences, Inc. (T.A. Sciences) recently announced the results of the Pivotal 2005 Anti-Aging Trial of TA-65, the first human trial ever to show demonstrated, measurable and positive anti-aging benefits from a Telomerase Activator. Statistically significant results were found in those taking TA-65 across several key conditions of aging:

    -- Improvement in immune system function

    -- Improvement in vision

    -- Enhancement of male sexual function

    -- Improvement in the condition of the skin

    -- Increased level of energy and sense of overall well being

The Pivotal 2005 Anti-Aging Trial was a double blind, placebo-controlled, 24 week study conducted in the USA involving 36 male subjects aged 60-85.

The most compelling result of the Trial was the profound and positive impact of TA-65 on the immune system, which normally declines with age, leading to many negative conditions commonly associated with aging.

Noel Thomas Patton, Founder and Chairman of TA Sciences said: "Taken together, the results of the Pivotal 2005 Anti-Aging Trial of TA-65 provide the first proof ever recorded of the vast, powerful, and tangible benefits of a Telomerase Activator in human aging. This trial has been invaluable to our establishment of the "PATTON PROTOCOL."

                        Find Out More on July 7, 2007


    On Saturday, July 7, 2007 at 6PM EST speakers include:


    -- Bill Andrews, Ph.D. Vice-President of research at Sierra Sciences Lab

       who, while Director of Molecular Biology at Geron Corporation was one

       of the principal discoverers of the telomerase genes.

    -- Jochen Kumm, Ph.D. Bio- Mathematics Director for the Stanford Genome

       Project.

    -- Physioage Medical Group Co-Founder Joseph Raffaele, M.D.

    -- TA Sciences founder Noel Patton.

The group will be disc ussing the details of the findings about TA-65 and answering caller questions. You can participate in this phone call at no cost, just by calling 1-866-463-5401 and entering a special code you can obtain by pre-registering at http://www.TASciences.com.

About TA Sciences:

The TA Sciences Center is located at 24 E. 64th Street in New York. The company offers its telomerase-activating molecule, TA-65, as part of the exclusive 12 month "PATTON PROTOCOL." TA-65 is sold under exclusive license from the Geron Corporation, the recognized worldwide leader in Telomere Biology.

CONTACT: TA Sciences, +1-212-588-8805

Web site: http://www.tasciences.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
2. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
3. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
6. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
9. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):